Chemotherapy of hormone-resistant stage D prostatic cancer.
D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011238:Prednimustine / Q000008:administration & dosage / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004961:Estramustine; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011238:Prednimustine; D002945:Cisplatin; D008558:Melphalan; D005472:Fluorouracil; D006918:Hydroxyurea; D008727:Methotrexate